Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

    ... Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy -resistant secondary acute myeloid leukemia (sAML). We used whole-genome sequencing to ...

    Research Article last updated 01/09/2012 - 2:17pm.

  2. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... multiple myeloma (MM) and myelodysplastic syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response ... on treatment and achieve optimal efficacy, is discussed. Secondary primary malignancies in MM and progression to acute myeloid leukemia ...

    Research Article last updated 11/16/2011 - 2:10pm.

  3. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... 30% bone marrow blasts . METHODS: This secondary analysis of the AZA-001 phase 3 study evaluated the time to first ... may enhance clinical benefit in patients with higher-risk MDS. Bone Marrow Diseases:  ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Myelodysplastic syndromes: an update on molecular pathology.

    ... The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterised by impaired ... of involved loci is increased in high-risk disease and secondary leukaemias. A better understanding of the pathogenesis of MDS can ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Risk of developing MDS and AML after radiation treatment for breast cancer

    ... to access the full report. Abstract # 6560 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) ...

    Research Review last updated 05/02/2016 - 9:32am.

  7. Eltrombopag Added to IST Yields Encouraging Results

    ... of eltrombopag may impact the risk of clonal evolution to MDS. A small portion (10-20%) of patients with aplastic anemia can develop MDS ... data following transplant. How important are the stated secondary outcomes: overall survival, overall response, relapse, and clonal ...

    Interview last updated 05/24/2017 - 7:44am.

  8. CASCADE (SGN33A-005)

    ... cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification ... chemotherapy for antecedent myelodysplastic syndrome (MDS First Name Last ...

    Clinical Trial last updated 06/19/2017 - 2:43pm.

  9. MEDALIST Trial

    ... very low, low, or intermediate Myelodysplastic syndrome (MDS) with ring sideroblasts (≥ 15%) who require Red blood cell (RBC) ... MDS associated with del 5q cytogenetic abnormality Secondary MDS , ie, MDS that is known to have arisen as the result of ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  10. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... PubMed Abstract:  Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease ... are found in approximately 50% of primary MDS and 80% of secondary MDS , which develops in the setting of prior chemotherapy ...

    Research Review last updated 05/02/2016 - 9:14am.